Movatterモバイル変換

Fosfenitoin

С Википедије, слободне енциклопедије

Fosfenitoin
Klinički podaci


Prodajno ime	Cerebyx, Prodilantin
Drugs.com	Monografija
Način primene	Intravenozno
Farmakokinetički podaci
Poluvreme eliminacije	15 minuta
Izlučivanje	Renalno

Identifikatori
CAS broj	93390-81-9^Y
ATC kod	N03AB05 (WHO)
PubChem	CID56339
DrugBank	DB01320^Y
ChemSpider	50839^Y
KEGG	C07840^Y
ChEMBL	CHEMBL919^Y
Hemijski podaci
Formula	C₁₆H₁₅N₂O₆P
Molarna masa	362,274
SMILES OP(O)(=O)OCN1C(=O)NC(C1=O)(C1=CC=CC=C1)C1=CC=CC=C1
InChI InChI=1S/C16H15N2O6P/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23/h1-10H,11H2,(H,17,20)(H2,21,22,23)^Y Key:XWLUWCNOOVRFPX-UHFFFAOYSA-N^Y

Fosfenitoin jeorgansko jedinjenje, koje sadrži 16atoma ugljenika i imamolekulsku masu od 362,274Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]

Osobine

[уреди |уреди извор]

Osobina	Vrednost
Broj akceptora vodonika	6
Broj donora vodonika	3
Broj rotacionih veza	5
Particioni koeficijent^[8] (ALogP)	1,7
Rastvorljivost^[9] (logS, log(mol/L))	-2,7
Polarna površina^[10] (PSA,Å²)	126,0

Reference

[уреди |уреди извор]

^Johnson J, Wrenn K: Inappropriate fosphenytoin use in the ED. Am J Emerg Med. 2001 Jul;19(4):293-4.PMID 11447516
^Applebaum J, Levine J, Belmaker RH: Intravenous fosphenytoin in acute mania. J Clin Psychiatry. 2003 Apr;64(4):408-9.PMID 12716241
^McCleane GJ: Intravenous infusion of fosphenytoin produces prolonged pain relief: a case report. J Pain. 2002 Apr;3(2):156-8.PMID 14622802
^Browne TR, Kugler AR, Eldon MA: Pharmacology and pharmacokinetics of fosphenytoin. Neurology. 1996 Jun;46(6 Suppl 1):S3-7.PMID 8649612 8649612
^Luszczki JJ: Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep. 2009 Mar-Apr;61(2):197-216.PMID 19443931
^Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011).„DrugBank 3.0: a comprehensive resource for omics research on drugs”.Nucleic Acids Res.39 (Database issue): D1035—41.PMC 3013709 .PMID 21059682.doi:10.1093/nar/gkq1126. уреди
^David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008).„DrugBank: a knowledgebase for drugs, drug actions and drug targets”.Nucleic acids research.36 (Database issue): D901—6.PMC 2238889 .PMID 18048412.doi:10.1093/nar/gkm958. уреди
^Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998).„Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”.J. Phys. Chem. A.102: 3762—3772.doi:10.1021/jp980230o.
^Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001).„Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”.Chem Inf. Comput. Sci.41: 1488—1493.PMID 11749573.doi:10.1021/ci000392t. уреди
^Ertl P.; Rohde B.; Selzer P. (2000).„Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”.J. Med. Chem.43: 3714—3717.PMID 11020286.doi:10.1021/jm000942e. уреди